CLSN Phase 3 interim analysis due this year. ARQL Phase 2 HCC data due early 2012.

Nov 10, 2011 No Comments by

ArQule, Inc. (NASDAQ: ARQL) noted that in the last quarter patient recruitment in the Phase 2 trial with tivantinib, an oral, selective inhibitor of the c-MET receptor tyrosine kinase, in hepatocellular carcinoma (HCC), had been completed and expects to have data available very early in 2012.

Celsion Corporation (NASDAQ: CLSN) maintained today that it interim analysis of its HEAT Phase 3 trial in patients with non-resectable primary liver cancer (hepatocellular carcinoma or HCC), is expected by the end of 2011, with a final data readout in late 2012.

Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that it expects to initiate a Phase 1-2 clinical trial of of ganetespib with radiation and chemotherapy by Q1 2012.

 

Daily News

About the author

Currently residing in New Zealand, Mr. A.Burden holds a Master of Commerce in International Business from the University of Sydney and used these skills together with his passion for investing to establish BioPharmCatalyst in June 2010 as a tool for investing decisions in the US pharmaceutical market. He spends much of his free time mountain biking, playing squash and hiking.
No Responses to “CLSN Phase 3 interim analysis due this year. ARQL Phase 2 HCC data due early 2012.”

Leave a Reply